Programming Durable Immune Responses To Vaccination
规划对疫苗接种的持久免疫反应
基本信息
- 批准号:10319526
- 负责人:
- 金额:$ 66.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-18 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAffinityAntibodiesAntibody ResponseAntigensAppearanceAxillary lymph node groupB-Cell ActivationB-Lymphocyte SubsetsB-LymphocytesBCL6 geneBloodBone MarrowCell CompartmentationCellsCessation of lifeChIP-seqClone CellsComparative Genomic AnalysisDataData SetExhibitsFeedbackFine needle aspiration biopsyFrequenciesGene ExpressionGenesGenetic TranscriptionGoalsHemagglutininHumanHumoral ImmunitiesIRF4 geneImmune responseImmunityImmunocompromised HostImmunoglobulin AImmunoglobulin Class SwitchingIndividualInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza vaccinationKineticsLongevityLoxP-flanked alleleMaintenanceMemory B-LymphocyteMolecularMusPathway interactionsPeripheralPhenotypePlasma CellsPlasmablastPublic HealthReactionResearchResourcesSamplingSeedsSeriesSerumStructure of germinal center of lymph nodeSurfaceTestingTranscriptUp-RegulationVaccinationVaccinesWorkbasecross reactivitydifferential expressiondraining lymph nodeexperimental studyfightinggenetic analysishuman pathogeninfluenza epidemicinfluenza virus straininfluenza virus vaccineinfluenzavirusinnovationinsightmouse modelnovelpandemic diseaseperipheral bloodprogramsrational designresponseseasonal influenzaself-renewalsingle-cell RNA sequencingstemtranscription factortranscription factor NF-AT c3transcriptome sequencinguniversal influenza vaccinevaccine-induced immunity
项目摘要
ABSTRACT
Influenza viruses cause up to 500,000 deaths around the globe annually. An ideal influenza vaccine must have
two essential attributes: one, it should be capable of inducing broadly cross-reactive antibodies that can
neutralize diverse influenza virus strains; and two, it must induce long-lived antibody responses to maintain
protective immunity for extended periods. Licensed seasonal influenza virus vaccines do neither – the antibody
response is of limited breadth and vaccine-induced immunity appears to be of short duration. Early work has
established that induction of hemagglutinin (HA)-specific antibodies is essential and sufficient for protection.
Despite the extensive efforts and resources that have been deployed to fight influenza over the past eight
decades, it remains a major public health threat. There are major gaps in our understanding of memory B cell
(MBC) responses to influenza virus vaccination in humans: (1) does influenza vaccination induce a GC
reaction in the draining lymph node? (2) if yes, how robust is that response in comparison to those induced by
vaccines that elicit more durable serum antibody responses? 3) are all peripheral MBCs that emerge after
vaccination GC-derived? 4) if yes, what is the phenotype of GC-derived antigen-specific B cells that are
destined to become LLPCs? 5) does influenza vaccination induces a sustained increase in the frequency of
bone marrow-resident LLPCs? 6) is there a correlation between the frequency of antigen-specific GC B cells
and the increase/maintenance in bone marrow LLPCs? Tackling these gaps will allow us to discern the cellular
components that are associated with durable antibody responses following vaccination in humans. In our
studies, we will address these outstanding questions through detailed phenotypic, functional and transcriptional
analysis of influenza vaccination-induced, HA-specific B cell responses isolated not only from the easily
accessible blood compartment, but also those isolated from the draining lymph nodes and the bone marrow
compartments. Our preliminary data show that there are at least two distinct subsets of vaccine-induced B cell
subsets that differ in the kinetics of their appearance in blood, isotype distribution, and differentiation potential.
Additionally, our transcriptional analyses reveal differential expression of key transcription factors, such as
TCF-1 that are associated broadly with isotype-switching and self-renewal capacity. Elucidating the origin and
fate of influenza vaccines-induced B cell responses is unarguably a major public health need and our findings
will potentially reveal the cellular and molecular determinants dictating not only the longevity, but also the
breadth of elicited antibody responses to influenza – and potentially other – vaccination in humans.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ali Hassan Ellebedy其他文献
Ali Hassan Ellebedy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ali Hassan Ellebedy', 18)}}的其他基金
Programming Long-lasting Immunity to Coronaviruses (PLUTO)
对冠状病毒进行持久免疫编程 (PLUTO)
- 批准号:
10549475 - 财政年份:2023
- 资助金额:
$ 66.76万 - 项目类别:
Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
开发针对革兰氏菌和革兰氏菌的保护性单克隆抗体
- 批准号:
10162826 - 财政年份:2021
- 资助金额:
$ 66.76万 - 项目类别:
Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
开发针对革兰氏菌和革兰氏菌的保护性单克隆抗体
- 批准号:
10577803 - 财政年份:2021
- 资助金额:
$ 66.76万 - 项目类别:
Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
开发针对革兰氏菌和革兰氏菌的保护性单克隆抗体
- 批准号:
10352467 - 财政年份:2021
- 资助金额:
$ 66.76万 - 项目类别:
Programming Durable Immune Responses To Vaccination
规划对疫苗接种的持久免疫反应
- 批准号:
10539283 - 财政年份:2018
- 资助金额:
$ 66.76万 - 项目类别:
Programming Durable Immune Responses To Vaccination
规划对疫苗接种的持久免疫反应
- 批准号:
10062811 - 财政年份:2018
- 资助金额:
$ 66.76万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 66.76万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 66.76万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 66.76万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 66.76万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 66.76万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 66.76万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 66.76万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 66.76万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 66.76万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 66.76万 - 项目类别: